Pharmacy Times Continuing Education™ (PTCE), based in Cranbury, N.J., presented a poster at the American Diabetes Association ($ADA) 2026 Scientific Sessions in New Orleans exploring educational strategies aimed at reducing clinical inertia in Type 2 diabetes management. The sessions ran June 5–8, drawing clinicians and researchers who collectively set treatment norms for one of the most prevalent chronic diseases in the United States. The presentation positions continuing medical education as an active tool for changing prescribing behavior — not merely conveying new science.
What Clinical Inertia Actually Means
Clinical inertia is the failure of a treating clinician to initiate or intensify therapy when a patient's treatment goals are not being met. In Type 2 diabetes, that failure is concrete: a patient remains at blood sugar levels that accelerate the risk of complications — nerve damage, kidney disease, cardiovascular events — while an available and appropriate treatment option goes unused. The problem is well-documented in chronic disease care broadly, but diabetes offers an especially clear case study because the disease is progressive, guideline-supported treatment options have expanded, and yet gaps between recommended and actual care persist.
Why the Education Layer Matters
PTCE's focus on educational strategy, rather than a new drug or device, reframes clinical inertia as a behavior problem rather than a knowledge gap. The research presented at the ADA sessions appears to examine how structured continuing education can shift what clinicians actually do at the point of care — particularly whether they escalate therapy when patients fall short of targets. That is a different, and arguably harder, question than whether clinicians know that escalation is indicated.
The Commercial Stakes Behind the Poster
Continuing education providers rarely command the ADA conference floor space that pharmaceutical and device companies do, but PTCE's presence at the Scientific Sessions signals that payers, health systems, and the healthcare education sector increasingly view behavior-change programming as a lever in outcomes-based care. Who pays for that programming — and whether it demonstrably reduces costly downstream complications — remains the central question for any organization looking to scale this work beyond conference posters.